TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31706553

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (DC)
Number of subjects: 851

Group type: COMPARATOR
Intervention: Blood cardioplegia (BC)
Number of subjects: 851
Study: 29878341

Group type: EXPERIMENTAL
Intervention: DFN-02 (sumatriptan 10 mg with DDM)
Number of subjects: 107
Study: 28013104

Group type: EXPERIMENTAL
Intervention: UNDERPIN-ICU program
Number of subjects: 8
Study: 26316137

Group type: EXPERIMENTAL
Intervention: Peroral image-guided gastrostomy (POG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiologically created pigtail gastrostomy (PG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both POG and PG
Number of subjects: 60
Study: 23320445

Group type: EXPERIMENTAL
Intervention: Alternative uses generation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA)
Number of subjects: 0
Study: 21500166

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18373223

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 97
Study: 16762887

Group type: EXPERIMENTAL
Intervention: Avastin plus irinotecan (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: FOLFIRI (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: FOLFOX7 (group C)
Number of subjects: 90
Study: 12699521

Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg kg(‐1) i.m. premedication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 50
Study: 11033836

Group type: COMPARATOR
Intervention: rhIL-11 (recombinant human interleukin-11)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhIL-11
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhIL-11 in combination with G-CSF (filgrastim)
Number of subjects: 0
Study: 9193196

Group type: EXPERIMENTAL
Intervention: High-dose quetiapine fumarate (<= 750 mg/d)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Low-dose quetiapine fumarate (<= 250 mg/d)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 7712685

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Captopril (50 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29983230

Group type: EXPERIMENTAL
Intervention: Resveratrol (500mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28030431

Group type: EXPERIMENTAL
Intervention: LCZ696/amlodipine (200/5 mg/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Amlodipine (5 mg/day)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 266
Study: 26220283

Group type: EXPERIMENTAL
Intervention: EndoRings colonoscopy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 116
Study: 24949107

Group type: EXPERIMENTAL
Intervention: Intervention group (mothers advised on caries prevention)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Comparison group (mothers not advised on caries prevention)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract, but implied as a separate group)
Number of subjects: 649
Study: 23061793

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 20552173

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17426316

Group type: COMPARATOR
Intervention: Standard In‐Person Behavioral Weight Control Program (SBWP)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intermittent Technology-Based Program (INT-TECH)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Continuous Technology-Based Program (CON-TECH)
Number of subjects: 57
Study: 15803442

Group type: EXPERIMENTAL
Intervention: Thrombolytic drug regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shrinkage estimation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0
Study: 12296638

Group type: EXPERIMENTAL
Intervention: Tirilazad treatment in patients with TBI
Number of subjects: 2177

Group type: COMPARATOR
Intervention: Control group (North America)
Number of subjects: 2177
Study: 9804028

Group type: EXPERIMENTAL
Intervention: Environmental targets and social cues (pointing, language)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study: 7637174

Group type: EXPERIMENTAL
Intervention: Ulinastatin (12,000 units.kg‐1) administered 15 min after starting CPB in the bubble oxygenator group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bubble oxygenator group without ulinastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Membrane oxygenator group
Number of subjects: 20
Study: 2482973

Group type: EXPERIMENTAL
Intervention: Avoidance behaviour
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Major depression
Number of subjects: 1168
Study: 73313

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 days every second week)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 30565718

Group type: EXPERIMENTAL
Intervention: High-protein oral nutrition supplement (S-ONS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29544579

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lactic acid producing probiotics
Number of subjects: 200
Study: 26856480

Group type: EXPERIMENTAL
Intervention: Multimedia nursing education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no multimedia nursing education)
Number of subjects: 100
Study: 24974806

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES-R)
Number of subjects: 60
Study: 23109023

Group type: EXPERIMENTAL
Intervention: Ciaglia technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Griggs technique
Number of subjects: 100
Study: 19579640

Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) 12-week group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) 6-week group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study: 17185047

Group type: EXPERIMENTAL
Intervention: Colistin dry powder inhalation (25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulised colistin (158 mg)
Number of subjects: 10
Study: 15584584

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (remifentanyl and propofol)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inhaled anaesthesia (isoflurane and fentanyl)
Number of subjects: 64
Study: 11466098

Group type: EXPERIMENTAL
Intervention: Experimental intervention (avoidance of pacifier use)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Experimental intervention
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Daily pacifier use (observational analysis)
Number of subjects: 281
Study: 9491905

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 94
Study: 8301443

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at doses from 5 to 80 ppm
Number of subjects: 23
Study: 2732981

Group type: COMPARATOR
Intervention: 250 mg metronidazole (two sponges per day for two days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1,000 mg metronidazole (one sponge per day for three days)
Number of subjects: 52
Study: 30940189

Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S‐1 [80‐120 mg] on days 1‐10, repeated every 14 days)
Number of subjects: 123

Group type: COMPARATOR
Intervention: S‐1 monotherapy (80‐120 mg/day on days 1‐14, repeated every 21 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1
Number of subjects: 123

Group type: COMPARATOR
Intervention: S‐1 monotherapy
Number of subjects: 123
Study: 28003540

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding to age 6 months (EBF-6)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding (nEBF-6)
Number of subjects: 756
Study: 25011019

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (85,300 IU weekly for 1 year)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 80
Study: 24682069

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 µg daily
Number of subjects: 7226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7226
Study: 21926942

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19956761

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g) given at 16-24 and 28-32 weeks gestation
Number of subjects: 2297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 2297
Study: 17725940

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally 3 times, beginning the day before ERCP until the night after the procedure.
Number of subjects: 320

Group type: COMPARATOR
Intervention: No preventive medication (Control group).
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally.
Number of subjects: 320
Study: 16095435

Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium as empiric therapy with physician notification
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control (no physician notification or ceftriaxone sodium)
Number of subjects: 449
Study: 11935149

Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 9895085

Group type: EXPERIMENTAL
Intervention: Sameridine 0.73 mg/kg (S-Large)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine 0.10 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sameridine 0.15 mg/kg (S-Small)
Number of subjects: 12
Study: 7744150

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei preparation (BLP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 1782929

Group type: EXPERIMENTAL
Intervention: 30 W every 3 min exercise protocol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 10 W/min exercise protocol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Crossing method for VT determination
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VE method for VT determination
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Graphical methods for VT determination
Number of subjects: 51
Study: 7057051

Group type: EXPERIMENTAL
Intervention: Fluocinonide ointment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5% Crude coal tar
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: White petrolatum
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (Fluocinonide)
Number of subjects: 25
Study: 30790396

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 27456461

Group type: EXPERIMENTAL
Intervention: Educative, self‐regulation intervention (blood pressure education sessions and 12 weeks of individual counseling)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Total sample (N = 118)
Number of subjects: 118
Study: 25319844

Group type: EXPERIMENTAL
Intervention: Bladder stimulation and lumbar paravertebral massage maneuvers
Number of subjects: 127

Group type: COMPARATOR
Intervention: Holding under the armpits (control group)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 23916044

Group type: EXPERIMENTAL
Intervention: Retigabine/ezogabine (600-1200 mg/d)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 21330907

Group type: EXPERIMENTAL
Intervention: 0.5% PRO2000 gel
Number of subjects: 3101

Group type: EXPERIMENTAL
Intervention: BufferGel
Number of subjects: 3101

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 3101

Group type: COMPARATOR
Intervention: No gel
Number of subjects: 3101
Study: 19813275

Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 82

Group type: COMPARATOR
Intervention: C5V (combined cisplatin, 5‐fluorouracil, and vincristine) without amifostine
Number of subjects: 82

Group type: COMPARATOR
Intervention: C5V without amifostine
Number of subjects: 82
Study: 16488829

Group type: EXPERIMENTAL
Intervention: HIV prevention program
Number of subjects: 496

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 496
Study: 14984396

Group type: EXPERIMENTAL
Intervention: Citalopram (mean dose 26.3 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 11679464

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg b.i.d. for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo twice daily for 6 months
Number of subjects: 60
Study: 9629687

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 121

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 121
Study: 7848404

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (chest roentgenography and bone scan every 6 months)
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Clinical follow-up (physical examination and mammography)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Intensive follow-up
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Clinical follow-up
Number of subjects: 1243
Study: 3414953

Group type: COMPARATOR
Intervention: Conventional suctioning (group I; n = 20; 15 s of endotracheal suction with no mechanical ventilation during suctioning)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bronchoscopic suctioning (group II; n = 20; bronchoscope Olympus 1 T 10; mechanical ventilation during suctioning)
Number of subjects: 40
Study: 29843529

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise along with mindfulness
Number of subjects: 70
Study: 28379084

Group type: EXPERIMENTAL
Intervention: 10-week mindfulness training intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active control (one hour extra break per week)
Number of subjects: 44
Study: 26408735

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 67
Study: 23832078

Group type: COMPARATOR
Intervention: ONS (Oral Nutritional Supplement)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ONS800 (ONS plus 800 mg beta-alanine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ONS1200 (ONS plus 1200 mg beta-alanine)
Number of subjects: 60
Study: 21727233

Group type: EXPERIMENTAL
Intervention: Self-help intervention for carers (ECHO intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention for carers (ECHO intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help and guided self-help versions
Number of subjects: 0
Study: 19545479

Group type: EXPERIMENTAL
Intervention: Anger treatment program
Number of subjects: 26
Study: 16434603

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy and cognitive behavioral therapy
Number of subjects: 66
Study: 15541080

Group type: EXPERIMENTAL
Intervention: Epidermal grafting on diabetic foot ulcers without exposed bones (n = 10)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Newly developed combination therapy for diabetic ulcers with exposed bones (n = 11)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard treatment for diabetic ulcers without exposed bones (n = 8)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard procedure for diabetic ulcers with exposed bones (n = 9)
Number of subjects: 38
Study: 11384563

Group type: EXPERIMENTAL
Intervention: Emedastine 0.05% eye drops, administered twice daily for 6 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Levocabastine 0.05% eye drops, administered twice daily for 6 weeks
Number of subjects: 222
Study: 9237139

Group type: EXPERIMENTAL
Intervention: Composipost system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stainless steel post and composite core
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cast gold alloy post and gold alloy core
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endodontically treated tooth only
Number of subjects: 0
Study: 7967703

Group type: EXPERIMENTAL
Intervention: Elimination of stasis and refreshment of spirit therapeutic group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group treated wholly with Western drugs
Number of subjects: 92
Study: 3174738

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nicotine gum (8 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mecamylamine pretreatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31253086

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Group RP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (Group Con)
Number of subjects: 46
Study: 28923140

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FIo2 ∼14.1%, equivalent to 3000 m)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normobaric normoxia (sea-level)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FIo2 ∼14.1%)
Number of subjects: 10
Study: 26749726

Group type: EXPERIMENTAL
Intervention: Modified Brostrom method repair (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Anatomical double-bundle reconstruction with free semitendinosus tendon autograft (Group B)
Number of subjects: 48
Study: 23345022

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Competitive Employment
Number of subjects: 157

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 157
Study: 21346162

Group type: EXPERIMENTAL
Intervention: Mood-elevating suggestion before ketamine administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: No suggestion provided (Control)
Number of subjects: 100
Study: 18483071

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older sedentary subjects
Number of subjects: 0
Study: 16764851

Group type: EXPERIMENTAL
Intervention: Antigens prepared from spiral form of H. pylori
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antigens prepared from coccoid cells of H. pylori
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Boosted antigens of coccoid cells
Number of subjects: 22
Study: 15129697

Group type: EXPERIMENTAL
Intervention: Anterior fractal dimension (FD) for FTLD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Anterior fractal dimension (FD) for AD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ratio of anterior to posterior FD for FTLD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ratio of anterior to posterior FD for AD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sensitivity of anterior FD and ratio of anterior to posterior FD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Specificity of anterior FD and ratio of anterior to posterior FD
Number of subjects: 53
Study: 11016666

Group type: EXPERIMENTAL
Intervention: 1% BKC applied after 20% SDS
Number of subjects: 54

Group type: COMPARATOR
Intervention: Water control applied after 20% SDS
Number of subjects: 54
Study: 8889949

Group type: EXPERIMENTAL
Intervention: Disodium octaborate tetrahydrate applied at 200 micrograms/cm2 on carpet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole-body dosimeters preventing contact with disodium octaborate tetrahydrate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Comparison of urine boron levels between groups
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Direct dermal contact with treated carpet
Number of subjects: 22
Study: 1504913

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 47
Study: 6344034

Group type: EXPERIMENTAL
Intervention: Fendosal 200 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Fendosal 400 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 30953165

Group type: EXPERIMENTAL
Intervention: BCm bonded to glass‐ceramic treated with HFS
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BCm bonded to glass‐ceramic treated with HF
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BCp bonded to glass‐ceramic treated with MDP
Number of subjects: 240
Study: 28008092

Group type: EXPERIMENTAL
Intervention: Intensive PT (45 minutes of intensive exercises/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Soft PT (20-min/d apart from respiratory needs)
Number of subjects: 104
Study: 26440233

Group type: EXPERIMENTAL
Intervention: Ketamine 0.8 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sodium thiopental 1.5 mg/kg
Number of subjects: 160
Study: 24140630

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day
Number of subjects: 7863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7863

Group type: EXPERIMENTAL
Intervention: Change in TnI levels
Number of subjects: 7863
Study: 21169822

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (n=106)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Direct laryngoscopy (n=106)
Number of subjects: 212